Skip to main content

Day: May 14, 2024

Bird Construction Inc. Announces 2024 First Quarter Financial Results

MISSISSAUGA, Ontario, May 14, 2024 (GLOBE NEWSWIRE) — “Bird continues to deliver strong results, with 28% year over year revenue growth and margin accretion setting the stage for significant further improvements in earnings and cash flow for full-year 2024 over 2023. The Company’s combined backlog of contracted and awarded work continues to grow with favourable embedded margins, and the accretive acquisition of NorCan Electric in January added new specialized self-perform capabilities and recurring revenue to Bird’s already extensive resume,” stated Teri McKibbon, President and CEO of Bird Construction. “The Company’s strategic focus on being a leading collaborative construction company continues to drive growth and better outcomes for all parties, and the strength of our balance sheet positions us to invest in profitable...

Continue reading

Prestige Consumer Healthcare Inc. Reports Fiscal Year 2024 Results

Revenue of $277.0 Million in Q4 and $1,125.4 Million in Fiscal 2024 Solid Consumption Trends in Q4 Offset by Near-Term Supply Chain Constraints Achieved Leverage Ratio of 2.8x at Year-End, Below Long-Term Target Board of Directors Authorize New $300 Million Share Repurchase Program Initial Full-Year Fiscal 2025 Organic Revenue Growth and EPS Outlook of Approximately 1% and $4.40 to $4.46, respectivelyTARRYTOWN, N.Y., May 14, 2024 (GLOBE NEWSWIRE) — Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2024. “Our full-year fiscal 2024 delivered stable earnings and cash flow, enabled by our leading brand portfolio and proven business strategy. However, our fourth quarter performance was affected by accelerated supply chain pressures late in the quarter,...

Continue reading

UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2024. “Our team remains focused on the enrollment and execution of our Phase 2b ASPIRE study in diabetic macular edema, comparing UBX1325 (foselutoclax) against aflibercept,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “We were pleased to not only have been able to upsize our ASPIRE study to 50 patients as previously announced, but we also were able to extend the duration of the study to 36 weeks in order to better assess the durability of UBX1325 compared to aflibercept after final dosing at week 16. Patients and practitioners...

Continue reading

Lowell Farms Inc. Announces Unaudited First Quarter 2024 Financial and Operational Results

SALINAS, Calif., May 14, 2024 (GLOBE NEWSWIRE) — Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California cannabis company with advanced distribution and production capabilities including extraction, manufacturing, sales and brand management, announces unaudited revenue and operating results for the first quarter of 2024 (ended March 31, 2024). All figures stated are in US Dollars. First Quarter Financial Highlights:Net revenue generated for the quarter ended March 31, 2024 decreased 35% to $4.9 million, as compared to $7.5 million for the first quarter last year. Net revenue increased 35% from $7.5 million in the fourth quarter of 2023.CPG revenue decreased 11% for the quarter ended March 31, 2024 compared to the quarter ended March 31, 2023 and increased 10% compared to the fourth quarter of 2023. Bulk Product...

Continue reading

FibroBiologics Files 2024 First Quarter Report

HOUSTON, May 14, 2024 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, with the U.S. Securities and Exchange Commission. The filing can be viewed through a link on FibroBiologics’ website at https://ir.fibrobiologics.com/sec-filings/quarterly-reports. About FibroBiologics Based in Houston, FibroBiologics is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally...

Continue reading

Capital Power announces a C$450 million Subordinated Notes offering

EDMONTON, Alberta, May 14, 2024 (GLOBE NEWSWIRE) — Capital Power Corporation (“Capital Power” or the “Company”) (TSX:CPX) announced today that it has priced a public offering in Canada of C$450M 8.125% Fixed-to-Fixed Rate Subordinated Notes, Series 2 due June 5, 2054 (the “Notes”). The Offering is expected to close on or about June 5, 2024. The Company intends to use the net proceeds from the sale of the Notes to repay certain amounts drawn on the Company’s credit facilities (which include amounts drawn for the acquisition of a 50% interest in New Harquahala Generating Company, LLC, and a 100% interest in CXA La Paloma, LLC, and related expenses, development purposes and in respect of ongoing operations), to redeem all of the Company’s outstanding Cumulative Minimum Rate Reset Preferred Shares, Series 11 (TSX: CPX.PR.K) (the “Preferred...

Continue reading

Draganfly Announces First Quarter Results of 2024

Vancouver, BC., May 14, 2024 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, is pleased to announce its first quarter financial results. Key Financial and Operational Highlights for Q1 2024:  ● Revenue for the first quarter of 2024 was $1,329,581 which represents a 45% quarter over quarter increase and was down 17% year over year. Product sales of $1,237,948 made up the bulk of the revenue with the remainder coming from drone services. This is compared to total Q1 Revenue in 2023 of $1,601,486.       ● Gross profit for Q1 2024 was $280,011 down $163,423 over the same period in 2023. Gross margin percentage for Q1 2024 was 21.1% compared to 27.7% in Q1 2023. Gross profit would have been $428,771...

Continue reading

TOFUTTI ANNOUNCES RESULTS FOR THE FISCAL QUARTER ENDED MARCH 30, 2024

Cranford, New Jersey, May 14, 2024 (GLOBE NEWSWIRE) — TOFUTTI BRANDS INC. (OTCQX Symbol: TOFB) today issued its results for the fiscal quarter ended March 30, 2024. Tofutti Brands reported net sales of $2,212,000, a decrease of $278,000 or 11%, from net sales of $2,490,000 for the fiscal quarter ended April 1, 2023. Sales of our vegan cheese products decreased to $1,809,000 in the thirteen weeks ended March 30, 2024 from $2,100,000 in the thirteen weeks ended April 1, 2023, due to increased competition in the vegan cheese category. Sales of our frozen dessert products increased slightly to $403,000 in the thirteen weeks ended March 30, 2024 from $390,000 for the thirteen weeks ended April 1, 2023. Our gross profit decreased to $470,000 for the thirteen weeks ended March 30, 2024 from $606,000 for the thirteen weeks ended April...

Continue reading

HeartCore Reports First Quarter 2024 Financial Results

NEW YORK and TOKYO, May 14, 2024 (GLOBE NEWSWIRE) — HeartCore Enterprises, Inc. (Nasdaq: HTCR) (“HeartCore” or “the Company”), a leading enterprise software and consulting services company based in Tokyo, reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 and Recent Operational HighlightsSold a Go IPO Client Warrant for $9 million. During the first quarter ended March 31, 2024, the Company received $5 million, with the remaining $4 million received in April 2024. Due to specific accounting treatments and stipulations in the warrant agreement, HeartCore will not recognize the $9 million as revenue on the balance sheet until the client becomes a publicly listed company, which is expected to occur in Fall 2024. Disbursed first dividend payment of $0.02 per share on May 3, 2024 Expanded partnership...

Continue reading

Peyto Reports First Quarter 2024 Results

CALGARY, Alberta, May 14, 2024 (GLOBE NEWSWIRE) — Peyto Exploration & Development Corp. (TSX: PEY) (“Peyto” or the “Company”)  is pleased to report operating and financial results for the first quarter of 2024. Q1 2024 Highlights:Delivered $204.6 million in funds from operations1,2, or $1.05/diluted share, which funded $113.8 million of capital expenditures3 and $64.2 million of dividends to shareholders. Peyto generated earnings of $99.9 million, or $0.51/diluted share, and reduced net debt4 by $23.2 million in the quarter. First quarter production volumes averaged 125,018 boe/d (647.2 MMcf/d of natural gas, 17,145 bbls/d of NGLs), a 21% increase year over year, mainly due to the Repsol Canada Energy Partnership acquisition that closed in the fourth quarter of 2023 (the “Repsol Acquisition”...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.